{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:19:31Z","timestamp":1790648371124,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03689-4","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T07:45:07Z","timestamp":1736754307000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anti-IL 17 biologics and pyoderma gangrenosum \u2013 therapeutic or causal?"],"prefix":"10.1007","volume":"317","author":[{"given":"Anna","family":"Wanzenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Keshock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4141-9468","authenticated-orcid":false,"given":"Naveed","family":"Sami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"issue":"2","key":"3689_CR1","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/iwj.13067","volume":"16","author":"H Ben Abdallah","year":"2019","unstructured":"Ben Abdallah H, Fogh K, Bech R (2019) Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: a semi-systematic review. Int Wound J 16(2):511\u2013521","journal-title":"Int Wound J"},{"issue":"6","key":"3689_CR2","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.5114\/aoms.2014.47827","volume":"10","author":"K Lis","year":"2014","unstructured":"Lis K, Kuzawi\u0144ska O, Ba\u0142kowiec-Iskra E (2014) Tumor necrosis factor inhibitors - state of knowledge. Arch Med Sci 10(6):1175\u20131185","journal-title":"Arch Med Sci"},{"issue":"7","key":"3689_CR3","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/ced.15183","volume":"47","author":"A Orita","year":"2022","unstructured":"Orita A, Hoshina D, Hirosaki K (2022) Pyoderma gangrenosum caused by secukinumab successfully treated with risankizumab: a case report and literature review. Clin Exp Dermatol 47(7):1372\u20131374","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"3689_CR4","doi-asserted-by":"publisher","first-page":"2235040","DOI":"10.1080\/09546634.2023.2235040","volume":"34","author":"C Avci","year":"2023","unstructured":"Avci C, Akin G, Akarsu S, Lebe B (2023) Pyoderma gangrenosum and Behcet\u2019s-like disease induced by secukinumab: a paradoxical drug reaction. J Dermatolog Treat 34(1):2235040","journal-title":"J Dermatolog Treat"},{"issue":"11","key":"3689_CR5","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1111\/jdv.15714","volume":"33","author":"CD Sadik","year":"2019","unstructured":"Sadik CD, Thieme M, Zillikens D, Terheyden P (2019) First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab. J Eur Acad Dermatol Venereol 33(11):e406\u2013e7","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"3689_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ced\/llac117","volume":"48","author":"IF Aromolo","year":"2023","unstructured":"Aromolo IF, Maronese CA, Moltrasio C, Boggio F, Violetti SA, Avallone G et al (2023) Genetic findings in a patient with paradoxical pyoderma gangrenosum induced by brodalumab. Clin Exp Dermatol 48(3):293\u2013295","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"3689_CR7","doi-asserted-by":"publisher","first-page":"e13161","DOI":"10.1111\/dth.13161","volume":"33","author":"U Wollina","year":"2020","unstructured":"Wollina U, Schonlebe J, Furll C (2020) Pyoderma gangrenosum induced by secukinumab-A late paradoxical drug reaction. Dermatol Ther 33(1):e13161","journal-title":"Dermatol Ther"},{"issue":"3","key":"3689_CR8","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1111\/1346-8138.14611","volume":"46","author":"K Jin","year":"2019","unstructured":"Jin K, Matsuzaki Y, Akasaka E, Nakano H, Sawamura D (2019) Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab. J Dermatol 46(3):e108\u2013e9","journal-title":"J Dermatol"},{"key":"3689_CR9","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.2147\/CCID.S412520","volume":"16","author":"Q Zhou","year":"2023","unstructured":"Zhou Q, Zhou S, Xiong H, Yang J, Yang Z, Zhou N et al (2023) A case of paradoxical reactions to Biologic Therapy for Psoriasis. Clin Cosmet Investig Dermatol 16:1493\u20131497","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"8","key":"3689_CR10","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jdcr.2020.06.011","volume":"6","author":"AJ Petty","year":"2020","unstructured":"Petty AJ, Whitley MJ, Balaban A, Ellington K, Marano AL (2020) Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab. JAAD Case Rep 6(8):731\u2013733","journal-title":"JAAD Case Rep"},{"key":"3689_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jdcr.2023.05.002","volume":"37","author":"AS Kao","year":"2023","unstructured":"Kao AS, King AD, Bardhi R, Daveluy S (2023) Targeted therapy with ixekizumab in pyoderma gangrenosum: a case series and a literature overview. JAAD Case Rep 37:49\u201353","journal-title":"JAAD Case Rep"},{"issue":"9","key":"3689_CR12","doi-asserted-by":"publisher","first-page":"e15716","DOI":"10.1111\/dth.15716","volume":"35","author":"AS Kao","year":"2022","unstructured":"Kao AS, King AD, Daveluy S (2022) Successful treatment of cabozantinib-induced pyoderma gangrenosum with ixekizumab therapy: a case report. Dermatol Ther 35(9):e15716","journal-title":"Dermatol Ther"},{"issue":"11","key":"3689_CR13","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jdcr.2020.08.033","volume":"6","author":"MW Tee","year":"2020","unstructured":"Tee MW, Avarbock AB, Ungar J, Frew JW (2020) Rapid resolution of pyoderma gangrenosum with brodalumab therapy. JAAD Case Rep 6(11):1167\u20131169","journal-title":"JAAD Case Rep"},{"key":"3689_CR14","doi-asserted-by":"publisher","first-page":"2050313X2094043","DOI":"10.1177\/2050313X20940430","volume":"8","author":"ML McPhie","year":"2020","unstructured":"McPhie ML, Kirchhof MG (2020) Pyoderma gangrenosum treated with secukinumab: a case report. SAGE Open Med Case Rep 8:2050313X20940430","journal-title":"SAGE Open Med Case Rep"},{"issue":"9","key":"3689_CR15","doi-asserted-by":"publisher","first-page":"e15669","DOI":"10.1111\/dth.15669","volume":"35","author":"J Coe","year":"2022","unstructured":"Coe J, Kudva S, Shams K (2022) Matching the dose to the disease: successful treatment of recalcitrant pyoderma gangrenosum using high-dose secukinumab. Dermatol Ther 35(9):e15669","journal-title":"Dermatol Ther"},{"key":"3689_CR16","doi-asserted-by":"crossref","unstructured":"Salvia G, Michelucci A, Granieri G, Manzo Margiotta F, Bevilacqua M, Fidanzi C et al (2023) An Integrated Systemic and Local Wound Management in recalcitrant Pyoderma Gangrenosum. Int J Low Extrem Wounds 0(0):15347346221148818","DOI":"10.1177\/15347346221148818"},{"key":"3689_CR17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.12688\/f1000research.52100.2","volume":"10","author":"G Nikolakis","year":"2021","unstructured":"Nikolakis G, Kreibich K, Vaiopoulos A, Kaleta K, Talas J, Becker M et al (2021) Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab. F1000Res 10:381","journal-title":"F1000Res"},{"issue":"7","key":"3689_CR18","doi-asserted-by":"publisher","first-page":"e15507","DOI":"10.1111\/dth.15507","volume":"35","author":"M Li","year":"2022","unstructured":"Li M, Xiang H, Liang Y, Xue L, Zhou X, Yang L et al (2022) Secukinumab for PASS syndrome: a new choice for therapeutic challenge? Dermatol Ther 35(7):e15507","journal-title":"Dermatol Ther"},{"issue":"11","key":"3689_CR19","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.36849\/JDD.2020.1123","volume":"19","author":"MI Gul","year":"2020","unstructured":"Gul MI, Singam V, Hanson C, Neill BC, Aires DJ, Rajpara AN (2020) Remission of Refractory PASH Syndrome using ixekizumab and doxycycline. J Drugs Dermatol 19(11):1123","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"3689_CR20","doi-asserted-by":"publisher","first-page":"e01309","DOI":"10.14309\/crj.0000000000001309","volume":"11","author":"A Zaher","year":"2024","unstructured":"Zaher A, Castillo M (2024) Paradoxical reaction and parastomal pyoderma Gangrenosum Emergence with Secukinumab Therapy. ACG Case Rep J 11(3):e01309","journal-title":"ACG Case Rep J"},{"issue":"4","key":"3689_CR21","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1111\/ajd.14266","volume":"65","author":"G Salvia","year":"2024","unstructured":"Salvia G, Bevilacqua M, Manzo Margiotta F, Michelucci A, Granieri G, Fidanzi C et al (2024) Switch from adalimumab to brodalumab as a possible trigger factor for the onset of pyoderma gangrenosum. Australas J Dermatol 65(4):e111\u2013e3","journal-title":"Australas J Dermatol"},{"key":"3689_CR22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jdcr.2021.08.021","volume":"16","author":"IR Pollack","year":"2021","unstructured":"Pollack IR, Wolner ZJ, Hammett J, Swerlick RA (2021) Pyoderma Gangrenosum in a patient on ixekizumab. JAAD Case Rep 16:152\u2013154","journal-title":"JAAD Case Rep"},{"key":"3689_CR23","doi-asserted-by":"crossref","unstructured":"Clemente-Hern\u00e1ndez B, \u00c1lvarez-Salafranca M, Muelas-Rives I, Ollero-Domenche L, Gracia-Caza\u00f1a T, Gilaberte Y (2024) Multifocal pyoderma gangrenosum induced by secukinumab in a patient with hidradenitis suppurativa. Indian J Dermatol Venereol Leprol 90:1\u20133","DOI":"10.25259\/IJDVL_329_2024"},{"issue":"1\u20132","key":"3689_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s12026-012-8276-8","volume":"52","author":"A Krstic","year":"2012","unstructured":"Krstic A, Mojsilovic S, Jovcic G, Bugarski D (2012) The potential of interleukin-17 to mediate hematopoietic response. Immunol Res 52(1\u20132):34\u201341","journal-title":"Immunol Res"},{"issue":"4","key":"3689_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1084\/jem.194.4.519","volume":"194","author":"P Ye","year":"2001","unstructured":"Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P et al (2001) Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 194(4):519\u2013527","journal-title":"J Exp Med"},{"issue":"1","key":"3689_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/cei.12394","volume":"178","author":"AV Marzano","year":"2014","unstructured":"Marzano AV, Fanoni D, Antiga E, Quaglino P, Caproni M, Crosti C et al (2014) Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet\u2019s syndrome. Clin Exp Immunol 178(1):48\u201356","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"3689_CR27","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.it.2017.01.006","volume":"38","author":"N Amatya","year":"2017","unstructured":"Amatya N, Garg AV, Gaffen SL (2017) IL-17 signaling: the Yin and the Yang. Trends Immunol 38(5):310\u2013322","journal-title":"Trends Immunol"},{"key":"3689_CR28","unstructured":"Schmieder SJ, Krishnamurthy K Pyoderma Gangrenosum. StatPearls. Treasure Island (FL)2024"},{"issue":"7560","key":"3689_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/bmj.333.7560.181","volume":"333","author":"T Brooklyn","year":"2006","unstructured":"Brooklyn T, Dunnill G, Probert C (2006) Diagnosis and treatment of pyoderma gangrenosum. BMJ 333(7560):181\u2013184","journal-title":"BMJ"},{"issue":"3","key":"3689_CR30","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7861\/clinmedicine.19-3-224","volume":"19","author":"C George","year":"2019","unstructured":"George C, Deroide F, Rustin M (2019) Pyoderma gangrenosum - a guide to diagnosis and management. Clin Med (Lond) 19(3):224\u2013228","journal-title":"Clin Med (Lond)"},{"key":"3689_CR31","doi-asserted-by":"crossref","unstructured":"Rendon A, Schakel K (2019) Psoriasis Pathogenesis and Treatment. Int J Mol Sci.;20(6)","DOI":"10.3390\/ijms20061475"},{"issue":"2","key":"3689_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.36849\/JDD.2020.4662","volume":"19","author":"A Toussi","year":"2020","unstructured":"Toussi A, Le ST, Barton VR, Ma C, Cheng MY, Sukhov A et al (2020) Successful management of Anti-TNF-Induced Psoriasis despite continuation of Therapy in a Pyoderma Gangrenosum patient. J Drugs Dermatol 19(2):199\u2013201","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"3689_CR33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.amjmed.2017.12.009","volume":"131","author":"J Pinard","year":"2018","unstructured":"Pinard J, Chiang DY, Mostaghimi A, Granter SR, Merola JF, Barkoudah E (2018) Wounds that would not heal: Pyoderma Gangrenosum. Am J Med 131(4):377\u2013379","journal-title":"Am J Med"},{"issue":"6","key":"3689_CR34","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/j.1365-2133.2011.10565.x","volume":"165","author":"AM Binus","year":"2011","unstructured":"Binus AM, Qureshi AA, Li VW, Winterfield LS (2011) Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol 165(6):1244\u20131250","journal-title":"Br J Dermatol"},{"issue":"10","key":"3689_CR35","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1001\/archdermatol.2011.168","volume":"147","author":"E Guenova","year":"2011","unstructured":"Guenova E, Teske A, Fehrenbacher B, Hoerber S, Adamczyk A, Schaller M et al (2011) Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol 147(10):1203\u20131205","journal-title":"Arch Dermatol"},{"key":"3689_CR36","doi-asserted-by":"crossref","unstructured":"Pastor-Fern\u00e1ndez G, Mariblanca IR, Navarro MN (2020) Decoding IL-23 Signaling Cascade for New Therapeutic opportunities. Cells.;9(9)","DOI":"10.3390\/cells9092044"},{"key":"3689_CR37","doi-asserted-by":"publisher","first-page":"637829","DOI":"10.3389\/fimmu.2021.637829","volume":"12","author":"C Schinocca","year":"2021","unstructured":"Schinocca C, Rizzo C, Fasano S, Grasso G, La Barbera L, Ciccia F et al (2021) Role of the IL-23\/IL-17 pathway in Rheumatic diseases: an overview. Front Immunol 12:637829","journal-title":"Front Immunol"},{"key":"3689_CR38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jdcr.2023.01.022","volume":"34","author":"SH Gu\u00e9nin","year":"2023","unstructured":"Gu\u00e9nin SH, Khattri S, Lebwohl MG (2023) Spesolimab use in treatment of pyoderma gangrenosum. JAAD Case Rep 34:18\u201322","journal-title":"JAAD Case Rep"},{"issue":"1","key":"3689_CR39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1093\/ced\/llad317","volume":"49","author":"L Ma","year":"2023","unstructured":"Ma L, Chen X, Guo Q, Qiao Z, Wang N, Pai P et al (2023) Rapid response to spesolimab in a patient with severe refractory pyoderma gangrenosum. Clin Exp Dermatol 49(1):82\u201384","journal-title":"Clin Exp Dermatol"},{"issue":"10","key":"3689_CR40","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1111\/jdv.19935","volume":"38","author":"K Sugiura","year":"2024","unstructured":"Sugiura K, Fujita H, Komine M, Yamanaka K, Akiyama M (2024) The role of interleukin-36 in health and disease states. J Eur Acad Dermatol Venereol 38(10):1910\u20131925","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"3689_CR41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40257-017-0308-7","volume":"19","author":"JY Wang","year":"2018","unstructured":"Wang JY, French LE, Shear NH, Amiri A, Alavi A (2018) Drug-Induced Pyoderma Gangrenosum: a review. Am J Clin Dermatol 19(1):67\u201377","journal-title":"Am J Clin Dermatol"},{"key":"3689_CR42","unstructured":"Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD)2012"},{"issue":"2","key":"3689_CR43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239\u2013245","journal-title":"Clin Pharmacol Ther"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03689-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03689-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03689-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T07:45:11Z","timestamp":1736754311000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03689-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3689"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03689-4","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"235"}}